Patient characteristics.

A total of 447 IBD patients (334 CD, 113 UC, 232 females, 51.9%) were included in this observational retrospective trial. Almost two thirds of all IBD patients (61.52%, n = 275, (214 CD, 61 UC)) had direct exposure to biologic treatment within 12 weeks to CD related surgery. Median follow-up overall was 45 months [range 0–113]. Remission or mild disease activity at date of CD related surgery was documented in only one quarter of IBD patients (25.7%, n = 97/377) whereas 74.3% of all patients (n = 280/377) had moderate to severe disease activity at date of surgery. For description of disease location and disease behavior, the Montreal classification was used [20]. With 73.9% of all patients (n = 326/447), most patients had any treatment at date of surgery with 275 patients receiving biologic treatment (61.5%). A total of 97 patients (21.7%) received corticosteroids at date of surgery. No significant differences were observed between the subgroups with respect to patients’ characteristics.